Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
$160,000 per dose! The first approved CAR-T therapy in China, Zevor-cel by CARsgen, announces its initial price for the treatment of multiple myeloma.
🌈 $160,000 per dose! 🌈
⭐The first approved CAR-T therapy in China, Zevor-cel by CARsgen, announces its initial price for the treatment of multiple myeloma.
multiple myeloma
Zevor-cel
🌦On March 5th, the fifth approved CAR-T therapy in China, Zevor-cel injection (Zevor-cel) by CARsgen, was priced at $116,000 for its initial release.
Zevor-cel injection is an autologous CAR-T product targeting BCMA. It is the fifth CAR-T therapy approved and marketed in China, following Axicabtagene Ciloleucel by Fosun Kite, Relmacabtagene Autoleucel by JW Therapeutics, Equecabtagene Autoleucel by IASO Bio, and Inaticabtagene Autoleucel by Juventas.
Cheapest CAR-T therapy
🌺Currently, the cheapest approved CAR-T therapy in the world is Inaticabtagene Autoleucel by Juventas. The price has dropped below one million RMB, at 999,000 RMB (equivalent to less than $140,000).
US CAR-T
🌼In 2017, the US FDA approved two CAR-T products, marking the beginning of the era of immunocellular therapy. CAR-T therapy has always been known for its high prices. Just how expensive is it? The two CAR-T therapies approved for sale in the United States are priced at $475,000 (Kymriah) and $373,000 (Yescarta), and these are just the prices of the drugs themselves. The total cost of the treatment far exceeds these amounts.
Multiple Myeloma
🌻For the treatment of multiple myeloma, there are currently two CAR-T products on the US market: Idecabtagene vicleucel by BMS/bluebird bio and ciltacabtagene autoleucel by Legend Bio. They are priced at $419,000 and $465,000, respectively, with a BCMA target and a complete response (CR) rate of 28% and 78%.
In China
⚡ there are also two CAR-T products on the market: Zevor-cel injection by CARsgen and Equecabtagene Autoleucel injection by IASO Bio. They are priced at $160,000 and $162,000, respectively, with the same BCMA target and CR rates as high as 78.6% and 82.4%.
🌤To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!
WhatsApp+8613717959070
doctor.huang@globecancer.com
#CARTtherapy #CancerTreatment #Immunotherapy #MultipleMyeloma #BCMA #Zevorcel #CARsgen #MedicalBreakthrough #HealthcareInnovation #PrecisionMedicine #PersonalizedMedicine #MedicalAdvancements #FightAgainstCancer #GlobalHealthcare #AffordableMedicine
#CancerResearch #PatientCare #MedicalTechnology #InnovativeTherapy #HopeForPatients
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Breaking News Alert! Exciting news for multiple myeloma patients! A groundbreaking CAR-T therapy has been approved for launch in China!
🚀 Breaking News Alert! 🚀
🎉 Exciting news for multiple myeloma patients! A groundbreaking CAR-T therapy has been approved for launch in China! 🎉
multiple myeloma
CARsgen
🔍On March 1st, 2024, CARsgen, a leading Chinese pharmaceutical company, proudly announced the official approval by the National Medical Products Administration (NMPA) of their innovative CAR-T cell immunotherapy product, Zevor-cel, targeting BCMA. This revolutionary treatment is specifically designed for adult patients with relapsed or refractory multiple myeloma who have undergone at least three prior lines of treatment, including a proteasome inhibitor and an immunomodulatory agent.
Zevor-cel
🌟 Zevor-cel marks CARsgen’s debut commercial product, promising a new ray of hope for patients. While the price remains undisclosed, anticipation is high as it is expected to be competitive with its counterparts. Stay tuned as we eagerly await the reveal of its pricing strategy!
💪At the 2023 ASH Annual Meeting, Zevor-cel’s impressive three-year follow-up data stole the spotlight, boasting a remarkable Overall Response Rate (ORR) of 100% and a median Progression-Free Survival (PFS) of 25.0 months. With a median Overall Survival (OS) yet to be reached, the two-year OS rate has already hit 100%, and the three-year OS rate stands at a remarkable 92.9%, underscoring its outstanding safety profile and offering renewed hope for patients battling relapsed or refractory multiple myeloma.
Multiple Myeloma
👍In terms of approved indications, it’s worth noting that the current portfolio of domestic CAR-T therapies in China caters to various hematologic malignancies. While FOSUNKITE and JW Therapeutics target lymphomas, JUVENTAS focuses on leukemia. CARsgen and IASO Bio, however, have set their sights on multiple myeloma, aligning perfectly with the pressing medical needs of patients in this category.
👏Let’s celebrate this remarkable milestone in the fight against multiple myeloma, as we continue to strive for better, more effective treatments to improve patients’ lives worldwide! 🌍 #TogetherWeCanBeatCancer
If you are interested in the latest cancer-fighting technologies and treatment methods in China, or if any of patients wish to learn more, our team is available to support and advise you and your patients at any time.
Website：[https://www.medtourcn.com/]
Whatsapp：+8613717959070
Email: doctor.huang@globecancer.com
🔍 #Zevorcel #CARsgen #MultipleMyeloma #CARTTherapy #MedicalBreakthrough #NMPAApproval #HopeForPatients #HealthcareInnovation #CancerTreatment #MedicalAdvancement